Tags

Type your tag names separated by a space and hit enter

Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients.
AIDS. 2010 Jun 01; 24(9):F31-5.AIDS

Abstract

OBJECTIVE

To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172).

DESIGN

Single center diagnostic study.

SETTING

Institutional HIV outpatient department of an urban university clinic.

PARTICIPANTS

Adult HIV-1-infected individuals.

INTERVENTION

Serum samples were taken before and 21 days after vaccination.

MAIN OUTCOME MEASURES

Antibody titers determined by hemagglutination inhibition assay. Seroconversion to vaccination was defined by either an antibody titer of 1: 10 or less before and of at least 1: 40 after or at least 1: 10 before and at least four-fold increase in antibody titer 21 days after single vaccination.

RESULTS

One hundred and sixty patients (125 men/35 women) were analyzed. Before vaccination, 23 patients (14.4%) had a hemagglutination inhibition assay titer of at least 1: 40. A median of 22 +/- 3 days after vaccination, 110 (69%) patients seroconverted. Seroconverters were younger (45.1 +/- 10.0 vs. 48.8 +/- 11.3 years; P = 0.04), had a higher CD4 cell count (532 +/- 227 vs. 475 +/- 281 cells/microl; P = 0.03) and were more likely to have received a previous H5N1 vaccination in 2009 (25 vs. 8%; P = 0.02) when compared to nonresponders. No other significant differences were found comparing the two groups (prevaccination hemagglutination inhibition assay titer of > or =1: 40, AIDS, HAART, HIV RNA PCR <50 copies/ml or CD4 nadir, CD4 and CD8 percentage, sex, BMI, chronic hepatitis B or C).

CONCLUSION

Seroconversion after one dose of a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine of HIV-infected patients was 69%. Studies to investigate whether a second dose of the vaccine will increase seroconversion rate are needed.

Authors+Show Affiliations

HIVCENTER, Frankfurt, Germany. markus.bickel@hivcenter.de <markus.bickel@hivcenter.de>No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20559034

Citation

Bickel, Markus, et al. "Low Rate of Seroconversion After Vaccination With a Split Virion, Adjuvanted Pandemic H1N1 Influenza Vaccine in HIV-1-infected Patients." AIDS (London, England), vol. 24, no. 9, 2010, pp. F31-5.
Bickel M, Wieters I, Khaykin P, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS. 2010;24(9):F31-5.
Bickel, M., Wieters, I., Khaykin, P., Nisius, G., Haberl, A., Stephan, C., Von Hentig, N., Herrmann, E., Doerr, H. W., Brodt, H. R., & Allwinn, R. (2010). Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AIDS (London, England), 24(9), F31-5. https://doi.org/10.1097/QAD.0b013e3283398da1
Bickel M, et al. Low Rate of Seroconversion After Vaccination With a Split Virion, Adjuvanted Pandemic H1N1 Influenza Vaccine in HIV-1-infected Patients. AIDS. 2010 Jun 1;24(9):F31-5. PubMed PMID: 20559034.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients. AU - Bickel,Markus, AU - Wieters,Imke, AU - Khaykin,Pavel, AU - Nisius,Gabi, AU - Haberl,Annette, AU - Stephan,Christoph, AU - Von Hentig,Nils, AU - Herrmann,Eva, AU - Doerr,Hans W, AU - Brodt,Hans R, AU - Allwinn,Regina, PY - 2010/6/19/entrez PY - 2010/6/19/pubmed PY - 2010/12/31/medline SP - F31 EP - 5 JF - AIDS (London, England) JO - AIDS VL - 24 IS - 9 N2 - OBJECTIVE: To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172). DESIGN: Single center diagnostic study. SETTING: Institutional HIV outpatient department of an urban university clinic. PARTICIPANTS: Adult HIV-1-infected individuals. INTERVENTION: Serum samples were taken before and 21 days after vaccination. MAIN OUTCOME MEASURES: Antibody titers determined by hemagglutination inhibition assay. Seroconversion to vaccination was defined by either an antibody titer of 1: 10 or less before and of at least 1: 40 after or at least 1: 10 before and at least four-fold increase in antibody titer 21 days after single vaccination. RESULTS: One hundred and sixty patients (125 men/35 women) were analyzed. Before vaccination, 23 patients (14.4%) had a hemagglutination inhibition assay titer of at least 1: 40. A median of 22 +/- 3 days after vaccination, 110 (69%) patients seroconverted. Seroconverters were younger (45.1 +/- 10.0 vs. 48.8 +/- 11.3 years; P = 0.04), had a higher CD4 cell count (532 +/- 227 vs. 475 +/- 281 cells/microl; P = 0.03) and were more likely to have received a previous H5N1 vaccination in 2009 (25 vs. 8%; P = 0.02) when compared to nonresponders. No other significant differences were found comparing the two groups (prevaccination hemagglutination inhibition assay titer of > or =1: 40, AIDS, HAART, HIV RNA PCR <50 copies/ml or CD4 nadir, CD4 and CD8 percentage, sex, BMI, chronic hepatitis B or C). CONCLUSION: Seroconversion after one dose of a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine of HIV-infected patients was 69%. Studies to investigate whether a second dose of the vaccine will increase seroconversion rate are needed. SN - 1473-5571 UR - https://www.unboundmedicine.com/medline/citation/20559034/Low_rate_of_seroconversion_after_vaccination_with_a_split_virion_adjuvanted_pandemic_H1N1_influenza_vaccine_in_HIV_1_infected_patients_ L2 - https://doi.org/10.1097/QAD.0b013e3283398da1 DB - PRIME DP - Unbound Medicine ER -